Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers

Aims: To assess the comparative drug systemic exposure of a reference (RF) and four test (Test I, Test II, Test III and Test IV) formulations of triclabendazole (TCBZ) in heifers. Methods: Thirty Holstein heifers were randomly distributed into five groups (n=6 per group). Animals in the RF group rec...

Descripción completa

Detalles Bibliográficos
Autores: Ortiz, P., Castope, N., Cabrera, M., Farias, Cristina Elena, Suarez, G., Lanusse, Carlos Edmundo, Alvarez, Luis Ignacio
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2014
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/33845
Acceso en línea:http://hdl.handle.net/11336/33845
Access Level:acceso abierto
Palabra clave:Flukicidal Control
Triclabendazole
Generic Formulations
Bioequivalence
https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
id AR_ca9b58fd49014cfc3d8deebc2dee4318
oai_identifier_str oai:ri.conicet.gov.ar:11336/33845
network_acronym_str AR
network_name_str Argentina
repository_id_str
dc.title.none.fl_str_mv Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers
title Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers
spellingShingle Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers
Ortiz, P.
Flukicidal Control
Triclabendazole
Generic Formulations
Bioequivalence
https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
title_short Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers
title_full Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers
title_fullStr Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers
title_full_unstemmed Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers
title_sort Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers
dc.creator.none.fl_str_mv Ortiz, P.
Castope, N.
Cabrera, M.
Farias, Cristina Elena
Suarez, G.
Lanusse, Carlos Edmundo
Alvarez, Luis Ignacio
author Ortiz, P.
author_facet Ortiz, P.
Castope, N.
Cabrera, M.
Farias, Cristina Elena
Suarez, G.
Lanusse, Carlos Edmundo
Alvarez, Luis Ignacio
author_role author
author2 Castope, N.
Cabrera, M.
Farias, Cristina Elena
Suarez, G.
Lanusse, Carlos Edmundo
Alvarez, Luis Ignacio
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Flukicidal Control
Triclabendazole
Generic Formulations
Bioequivalence
https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
topic Flukicidal Control
Triclabendazole
Generic Formulations
Bioequivalence
https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
description Aims: To assess the comparative drug systemic exposure of a reference (RF) and four test (Test I, Test II, Test III and Test IV) formulations of triclabendazole (TCBZ) in heifers. Methods: Thirty Holstein heifers were randomly distributed into five groups (n=6 per group). Animals in the RF group received the reference formulation (Fasinex), and those in the other groups received different commercially available TCBZ formulations (Test I, Test II, Test III and Test IV). All treatments were orally administered at 12 mg/kg bodyweight. The concentrations of TCBZ metabolites in plasma between 0 and 168 hours after treatment were quantified by high-performance liquid chromatography (HPLC). Results: Triclabendazole sulphoxide (TCBZ.SO) and TCBZ-sulphone (TCBZ.SO2) were the only analytes recovered in plasma. Only the Test I formulation did not differ from the RF for all pharmacokinetic parameters measured for either metabolite (p>0.8). The TCBZ.SO area under the concentration vs. time curve for Test II formulation (268.9 µg.h/mL) was lower, and for Test III (619.9 µg.h/mL) and Test IV (683.4 µg.h/mL) was higher, than the RF (418.1 µg.h/mL) (p<0.005). Conclusion: Based on the currently available bioequivalence criteria, the only test formulation under evaluation that could be considered equivalent to the RF was the Test I formulation, which demonstrated an equivalent systemic exposure for the active TCBZ.SO metabolite. This comparison of TCBZ pioneer and test formulations in cattle raises awareness of the need for further quality control for drug approval in the veterinary pharmaceutical field in many regions of the world.
publishDate 2014
dc.date.none.fl_str_mv 2014-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/33845
Ortiz, P.; Castope, N.; Cabrera, M.; Farias, Cristina Elena; Suarez, G.; et al.; Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers; Taylor & Francis; New Zealand Veterinary Journal; 62; 5; 7-2014; 279-285
0048-0169
CONICET Digital
CONICET
url http://hdl.handle.net/11336/33845
identifier_str_mv Ortiz, P.; Castope, N.; Cabrera, M.; Farias, Cristina Elena; Suarez, G.; et al.; Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers; Taylor & Francis; New Zealand Veterinary Journal; 62; 5; 7-2014; 279-285
0048-0169
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1080/00480169.2014.925411
info:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/full/10.1080/00480169.2014.925411
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1799195191413833728
spelling Pharmacokinetic evaluation of different generic triclabendazole formulations in heifersOrtiz, P.Castope, N.Cabrera, M.Farias, Cristina ElenaSuarez, G.Lanusse, Carlos EdmundoAlvarez, Luis IgnacioFlukicidal ControlTriclabendazoleGeneric FormulationsBioequivalencehttps://purl.org/becyt/ford/4.3https://purl.org/becyt/ford/4Aims: To assess the comparative drug systemic exposure of a reference (RF) and four test (Test I, Test II, Test III and Test IV) formulations of triclabendazole (TCBZ) in heifers. Methods: Thirty Holstein heifers were randomly distributed into five groups (n=6 per group). Animals in the RF group received the reference formulation (Fasinex), and those in the other groups received different commercially available TCBZ formulations (Test I, Test II, Test III and Test IV). All treatments were orally administered at 12 mg/kg bodyweight. The concentrations of TCBZ metabolites in plasma between 0 and 168 hours after treatment were quantified by high-performance liquid chromatography (HPLC). Results: Triclabendazole sulphoxide (TCBZ.SO) and TCBZ-sulphone (TCBZ.SO2) were the only analytes recovered in plasma. Only the Test I formulation did not differ from the RF for all pharmacokinetic parameters measured for either metabolite (p>0.8). The TCBZ.SO area under the concentration vs. time curve for Test II formulation (268.9 µg.h/mL) was lower, and for Test III (619.9 µg.h/mL) and Test IV (683.4 µg.h/mL) was higher, than the RF (418.1 µg.h/mL) (p<0.005). Conclusion: Based on the currently available bioequivalence criteria, the only test formulation under evaluation that could be considered equivalent to the RF was the Test I formulation, which demonstrated an equivalent systemic exposure for the active TCBZ.SO metabolite. This comparison of TCBZ pioneer and test formulations in cattle raises awareness of the need for further quality control for drug approval in the veterinary pharmaceutical field in many regions of the world.Fil: Ortiz, P.. Universidad Nacional de Cajamarca; PerúFil: Castope, N.. Universidad Nacional de Cajamarca; PerúFil: Cabrera, M.. Universidad Nacional de Cajamarca; PerúFil: Farias, Cristina Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Suarez, G.. Universidad de la República; UruguayFil: Lanusse, Carlos Edmundo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Alvarez, Luis Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaTaylor & Francis2014-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/33845Ortiz, P.; Castope, N.; Cabrera, M.; Farias, Cristina Elena; Suarez, G.; et al.; Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers; Taylor & Francis; New Zealand Veterinary Journal; 62; 5; 7-2014; 279-2850048-0169CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1080/00480169.2014.925411info:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/full/10.1080/00480169.2014.925411info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2024-05-08T13:45:46Zoai:ri.conicet.gov.ar:11336/33845instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982024-05-08 13:45:47.056CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
score 15,811543

Similares en LA Referencia